Swiss Market Slightly Declines Ahead of Holiday Break
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy ROG?
Source: NASDAQ.COM
- Market Performance: The Swiss market slightly declined on Monday, with the benchmark SMI settling at 13,163.66 points, down 8.19 points or 0.06%, reflecting cautious investor sentiment ahead of the Christmas holidays.
- Trading Activity: Despite the overall market weakness, Amrize rose by approximately 1.7% and Partners Group gained nearly 1.2%, indicating that certain stocks still possess appeal, potentially attracting short-term investors' interest.
- Legal Risks: A Swiss court has decided to admit a climate change lawsuit against Holcim, alleging insufficient action on carbon emissions, which could negatively impact the company's reputation and future operations.
- Drug Pricing Impact: Roche's CEO indicated that agreements between pharmaceutical companies and Washington to reduce drug prices may lead to increased costs for new drugs in Switzerland, posing challenges to the company's future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROG
Wall Street analysts forecast ROG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROG is 281.18 USD with a low forecast of 105.00 USD and a high forecast of 457.36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 102.100
Low
105.00
Averages
281.18
High
457.36
Current: 102.100
Low
105.00
Averages
281.18
High
457.36
About ROG
Rogers Corporation designs, develops, manufactures and sells engineered materials and components. Its segments include Advanced Electronics Solutions (AES) and Elastomeric Material Solutions (EMS) and Other. The AES segment designs, develops, manufactures and sells circuit materials, ceramic substrate materials, busbars and cooling solutions for applications in the EV/HEV, automotive, aerospace and defense, renewable energy, wireless infrastructure, mass transit, industrial, connected devices and wired infrastructure markets. The EMS segment designs, develops, manufactures and sells engineered material solutions for a variety of applications and markets. These include polyurethane and silicone materials used in cushioning, gasketing and sealing, and vibration management applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, and other markets. The Other segment consists of elastomer components for applications in the general industrial market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rogers Corporation to Announce Q4 and Full Year 2025 Results
- Earnings Announcement Schedule: Rogers Corporation plans to release its fourth quarter and full year 2025 financial results on February 17, 2026, after market close, reflecting its ongoing performance in the engineered materials sector.
- Conference Call Details: Following the earnings release, a conference call will be held at 5:00 PM ET, hosted by Interim CEO Ali El-Haj, with CFO Laura Russell joining, enhancing investor communication and engagement.
- Live Webcast Access: Investors can access the live webcast and related slide presentation through Rogers' Investor Relations website, ensuring transparency and increasing investor participation in the company's financial updates.
- Company Background Information: Rogers Corporation is a global leader in engineered materials, focusing on providing innovative solutions for electric vehicles, renewable energy, and wireless infrastructure, showcasing its broad applications and market impact across various industries.
See More
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
- Introduction of Weight-Loss Pills: The first effective weight-loss pills are expected to be available on the market this year.
- Obesity Drug Developments: There will be significant news and developments regarding obesity drugs throughout the year, as noted by Guggenheim Securities.
See More
Third Avenue Value Fund Increases Boise Cascade Stake by $19.16 Million
- New Portfolio Addition: In Q4 2025, Third Avenue Value Fund added 271,872 shares of Boise Cascade Co valued at $19.16 million, representing 2.49% of the portfolio, indicating confidence in the company's future growth potential.
- Position Increase: The fund increased its stake in Conduit Holdings Ltd by 976,307 shares, a 39.07% rise, bringing total holdings to 3,474,876 shares, reflecting optimism about the company's financial health and market outlook.
- Exit Strategy: The fund completely exited its position in Deutsche Bank AG by selling 882,569 shares, resulting in a -4.26% impact on the portfolio, which suggests a cautious stance on the stock's future performance.
- Position Reduction: Third Avenue reduced its stake in Bayerische Motoren Werke AG by 23,725 shares, impacting the portfolio by -0.33%, indicating concerns about the stock's short-term performance, despite a 12.78% return over the past three months.
See More
Swiss Market Slightly Declines Ahead of Holiday Break
- Market Performance: The Swiss market slightly declined on Monday, with the benchmark SMI settling at 13,163.66 points, down 8.19 points or 0.06%, reflecting cautious investor sentiment ahead of the Christmas holidays.
- Trading Activity: Despite the overall market weakness, Amrize rose by approximately 1.7% and Partners Group gained nearly 1.2%, indicating that certain stocks still possess appeal, potentially attracting short-term investors' interest.
- Legal Risks: A Swiss court has decided to admit a climate change lawsuit against Holcim, alleging insufficient action on carbon emissions, which could negatively impact the company's reputation and future operations.
- Drug Pricing Impact: Roche's CEO indicated that agreements between pharmaceutical companies and Washington to reduce drug prices may lead to increased costs for new drugs in Switzerland, posing challenges to the company's future profitability.
See More
Lilly's Stock Has Tripled Due to Weight-Loss Medications: Here's Why It Appears Undervalued.
Growth Potential of Obesity Meds: The potential for growth in the obesity medication market is recognized, but there may be more to it than currently understood.
Future Developments: Two significant developments anticipated in 2026 could accelerate market growth beyond investor expectations.
Investor Predictions: Current investor predictions may not fully account for the rapid advancements and changes in the obesity medication landscape.
Market Dynamics: The evolving dynamics in the obesity treatment sector suggest a promising outlook for the industry in the coming years.
See More
AbbVie and Other Drugmakers Reach Price Reduction Agreements with U.S. Government
- Price Reduction Agreements: AbbVie, Bristol Myers Squibb, Gilead, and other drugmakers are expected to announce agreements with the U.S. government on Friday to lower certain prescription drug prices, aiming to address the high drug costs in the U.S., which could impact these companies' revenue structures.
- Market Response Stabilized: Although the U.S. government may implement stricter drug price controls, the agreements reached so far have alleviated investor concerns, demonstrating the market's adaptability to drug pricing reforms.
- Impact on Medicaid Spending: Analysts note that while Medicaid accounts for only about 10% of U.S. drug spending, its price discounts exceed 80% in some cases, which may influence drugmakers' pricing strategies and profit margins.
- Industry Dynamics Shift: As more drug companies negotiate with the government, price competition within the industry is expected to intensify, potentially leading to an overall decline in profit levels in the drug market, prompting companies to reassess their market positioning and strategic direction.
See More
Rogers Corporation to Announce Q4 and Full Year 2025 Results
- Earnings Announcement Schedule: Rogers Corporation plans to release its fourth quarter and full year 2025 financial results on February 17, 2026, after market close, reflecting its ongoing performance in the engineered materials sector.
- Conference Call Details: Following the earnings release, a conference call will be held at 5:00 PM ET, hosted by Interim CEO Ali El-Haj, with CFO Laura Russell joining, enhancing investor communication and engagement.
- Live Webcast Access: Investors can access the live webcast and related slide presentation through Rogers' Investor Relations website, ensuring transparency and increasing investor participation in the company's financial updates.
- Company Background Information: Rogers Corporation is a global leader in engineered materials, focusing on providing innovative solutions for electric vehicles, renewable energy, and wireless infrastructure, showcasing its broad applications and market impact across various industries.
See More
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
- Introduction of Weight-Loss Pills: The first effective weight-loss pills are expected to be available on the market this year.
- Obesity Drug Developments: There will be significant news and developments regarding obesity drugs throughout the year, as noted by Guggenheim Securities.
See More
Third Avenue Value Fund Increases Boise Cascade Stake by $19.16 Million
- New Portfolio Addition: In Q4 2025, Third Avenue Value Fund added 271,872 shares of Boise Cascade Co valued at $19.16 million, representing 2.49% of the portfolio, indicating confidence in the company's future growth potential.
- Position Increase: The fund increased its stake in Conduit Holdings Ltd by 976,307 shares, a 39.07% rise, bringing total holdings to 3,474,876 shares, reflecting optimism about the company's financial health and market outlook.
- Exit Strategy: The fund completely exited its position in Deutsche Bank AG by selling 882,569 shares, resulting in a -4.26% impact on the portfolio, which suggests a cautious stance on the stock's future performance.
- Position Reduction: Third Avenue reduced its stake in Bayerische Motoren Werke AG by 23,725 shares, impacting the portfolio by -0.33%, indicating concerns about the stock's short-term performance, despite a 12.78% return over the past three months.
See More
Swiss Market Slightly Declines Ahead of Holiday Break
- Market Performance: The Swiss market slightly declined on Monday, with the benchmark SMI settling at 13,163.66 points, down 8.19 points or 0.06%, reflecting cautious investor sentiment ahead of the Christmas holidays.
- Trading Activity: Despite the overall market weakness, Amrize rose by approximately 1.7% and Partners Group gained nearly 1.2%, indicating that certain stocks still possess appeal, potentially attracting short-term investors' interest.
- Legal Risks: A Swiss court has decided to admit a climate change lawsuit against Holcim, alleging insufficient action on carbon emissions, which could negatively impact the company's reputation and future operations.
- Drug Pricing Impact: Roche's CEO indicated that agreements between pharmaceutical companies and Washington to reduce drug prices may lead to increased costs for new drugs in Switzerland, posing challenges to the company's future profitability.
See More
Lilly's Stock Has Tripled Due to Weight-Loss Medications: Here's Why It Appears Undervalued.
Growth Potential of Obesity Meds: The potential for growth in the obesity medication market is recognized, but there may be more to it than currently understood.
Future Developments: Two significant developments anticipated in 2026 could accelerate market growth beyond investor expectations.
Investor Predictions: Current investor predictions may not fully account for the rapid advancements and changes in the obesity medication landscape.
Market Dynamics: The evolving dynamics in the obesity treatment sector suggest a promising outlook for the industry in the coming years.
See More
AbbVie and Other Drugmakers Reach Price Reduction Agreements with U.S. Government
- Price Reduction Agreements: AbbVie, Bristol Myers Squibb, Gilead, and other drugmakers are expected to announce agreements with the U.S. government on Friday to lower certain prescription drug prices, aiming to address the high drug costs in the U.S., which could impact these companies' revenue structures.
- Market Response Stabilized: Although the U.S. government may implement stricter drug price controls, the agreements reached so far have alleviated investor concerns, demonstrating the market's adaptability to drug pricing reforms.
- Impact on Medicaid Spending: Analysts note that while Medicaid accounts for only about 10% of U.S. drug spending, its price discounts exceed 80% in some cases, which may influence drugmakers' pricing strategies and profit margins.
- Industry Dynamics Shift: As more drug companies negotiate with the government, price competition within the industry is expected to intensify, potentially leading to an overall decline in profit levels in the drug market, prompting companies to reassess their market positioning and strategic direction.
See More
